Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant...

Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA

Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting ( Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA )

Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers

Dr Sibylle Loibl - German Breast Cancer Group

Current indications for CDK 4/6 inhibitors (plus antiestrogen), biomarkers ( Dr Sibylle Loibl - German Breast Cancer Group )

Coming of age for CDK 4/6 inhibitors: Interactive session and close

Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy

Coming of age for CDK 4/6 inhibitors: Interactive session and close ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )

Biomarkers of sensitivity and resistance

Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Biomarkers of sensitivity and resistance ( Dr Joan Seoane - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Editor's ESMO 2016 roundup

Prof Gordon McVie - Editor in Chief, ecancer

Editor's ESMO 2016 roundup ( Prof Gordon McVie - Editor in Chief, ecancer )

PDL-1 assay concordance

Dr Jill Walker - AstraZeneca, UK

PDL-1 assay concordance ( Dr Jill Walker - AstraZeneca, UK )

CDK4/6 inhibition: PALOMA2 versus MONALEESA2

Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria

CDK4/6 inhibition: PALOMA2 versus MONALEESA2 ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )

First evidence of significant clinical activity of PD1 inhibition in metastatic...

Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University...

First evidence of significant clinical activity of PD1 inhibition in metastatic prostate cancer ( Dr Julie Graff - Knight Cancer Institute, Oregon Health & Science University, Portland, USA )

ESMO 2016 conference highlights

Dr Bishal Gyawali - Nagoya University, Nagoya, Japan

ESMO 2016 conference highlights ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1...

Dr Omid Hamid - The Angeles Clinic, California, USA

Combination of MEDI0680, an anti-PD-1 antibody, with durvalumab, an anti-PD-L1 antibody: ( Dr Omid Hamid - The Angeles Clinic, California, USA )

ESMO 2016 prostate cancer highlights

Dr Eleni Efstathiou, Prof Karim Fizazi, Dr Chris Parker

ESMO 2016 prostate cancer highlights ( Dr Eleni Efstathiou, Prof Karim Fizazi, Dr Chris Parker )

Oncolytic virotherapy using coxsackie virus

Dr Hardev Pandha - University of Surrey, Guildford, UK

Oncolytic virotherapy using coxsackie virus ( Dr Hardev Pandha - University of Surrey, Guildford, UK )

More from ecancer